DHNASDAQHealthcare

DEFINITIVE HEALTHCARE CORP

Public company snapshot, recent ticker-linked headlines, and a path into evidence-backed AI research.

Latest price

$1.12

+0.00%

Yahoo Finance · 10/30/2026

Industry: Health Information ServicesCategory: Domestic Common StockCurrency: USDNews: 1 recent

Analyze DH free

One-year price history

Adjusted daily closes · 252 observations · as of Oct 30, 2026

Historical data, not a forecast

1 month

+19.7%

3 months

+60.0%

6 months

+13.6%

1 year

-58.2%

Year to date

-61.0%

52-week range

$0.63 – $2.93

Fundamental snapshot

Latest reported period: Jun 30, 2026

Sharadar reported data

Market cap

$119.6M

P/E

-0.7

P/B

0.8

P/S

0.5

Revenue

$232.7M

Net income

-$168.2M

Diluted EPS

-1.61

Gross margin

75.20%

Net margin

-72.30%

Return on equity

-78.50%

Total debt

$167.06M

Cash

$170.87M

Free cash flow

$28.56M

Latest eight reported quarters

Reported quarterly values, newest first

Period	Revenue	Net income	Gross margin	Net margin	Free cash flow
Jun 30, 2026	$55.2M	-$5.42M	73.50%	-9.80%	$8.51M
Mar 31, 2026	$55.93M	-$138.62M	74.50%	-247.90%	$8.36M
Dec 31, 2025	$61.53M	-$9.32M	76.20%	-15.10%	-$1.72M
Sep 30, 2025	$60.05M	-$14.84M	76.60%	-24.70%	$13.41M
Jun 30, 2025	$60.75M	-$7.55M	76.70%	-12.40%	$7.01M
Mar 31, 2025	$59.19M	-$107.23M	73.90%	-181.20%	$18.36M
Dec 31, 2024	$62.29M	-$59.08M	76.40%	-94.80%	-$2.77M
Sep 30, 2024	$62.7M	-$130.9M	78.20%	-208.80%	$18.67M

Reported figures can reflect company reporting conventions, restatements, or sector-specific accounting. Verify against filings before relying on a valuation comparison.

Recent DH news

All market news

ad-hoc-news.de·Oct 31, 202667 signal

Danaher stock: Wall Street Zen upgrade adds to bullish analyst view

Wall Street Zen upgraded Danaher (DHR) stock from Hold to Buy on October 26, contributing to a bullish analyst view. This upgrade, along with several price target increases from firms like TD Cowen and JPMorgan, followed Danaher's stronger-than-expected third-quarter results. While respiratory demand remains a headwind, the company improved its 2026 adjusted earnings outlook and showed stronger execution in life sciences, biotechnology, and diagnostics.

Original source